The AstraZeneca PLC ADR AZN rallied 1.48% to $70.08 Monday, on what proved to be an all-around mixed trading session for the ...

Shares of AstraZeneca PLC AZN rallied 1.18% to £111.80 Monday, on what proved to be an all-around positive trading session ...

AstraZeneca announced that this week it has received two positive recommendations from the National Institute for Health and Care Excellence (NICE) for the treatment of lung cancer patients across ...

There was a 65% increase in the number of children and young people being admitted to general acute medical wards in hospitals in England because of a mental health concern between 2012 and 2022, ...

J.P. Morgan analyst James Gordon maintained a Buy rating on AstraZeneca (AZN – Research Report) today and set a price target of £140.00. The ...

Daiichi Sankyo and AstraZeneca’s (AZN) biologics license application for datopotamab deruxtecan has been accepted and granted priority review in the U.S. for the treatment of adult patients with ...

AstraZeneca still trades at a premium valuation, but several factors limit its upside potential in the next visible period. There are three negative takeaways from China. IRA could also ...

A man has been left seriously injured after a machete fight broke out on Oxford Street in the early hours of New Year’s Day. Two men were caught fighting with the weapons at around 3am ...

UK-based pharmaceutical giant AstraZeneca has announced plans to restructure its biopharma unit to concentrate on next-generation therapeutics. “In the Biopharmaceutical Business Unit, we are now ...

IT worker can continue legal battle against pharmaceutical giant after judge rules that impact of skin condition makes him a disabled person An IT worker has won a legal battle to sue AstraZeneca ...

AstraZeneca India has laid off over 125 employees in its biopharmaceutical business unit, including senior managers and sales executives. The job cuts are part of a strategic restructuring due to loss ...

LONDON, Dec 24 (Reuters) - AstraZeneca (AZN.L), opens new tab has voluntarily withdrawn its marketing authorisation application with the EU's medicines regulator for its experimental precision ...